Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 4Completed 4Not yet recruiting 2Active not recruiting 2Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Liver Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 111Carboplatin 45Nivolumab 41Paclitaxel 34Cyclophosphamide 32Cisplatin 32Gemcitabine 30atezolizumab 27venetoclax 25Specimen Handling 25Magnetic Resonance Spectroscopy 24Pemetrexed 23fludarabine 22Docetaxel 22Biopsy 22Radiotherapy 21Ipilimumab 21Bevacizumab 21Azacitidine 21Radiosurgery 18Dexamethasone 18durvalumab 17Fluorouracil 17Cetuximab 16fludarabine phosphate 14Trastuzumab 14tislelizumab 13Leucovorin 13Cytarabine 13olaparib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Vancomycin × 1 year × Clear all
NCT03785210 2026-02-23

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
22 enrolled 13 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡